Amanote Research
Register
Sign In
Pms73 - Bright Future for the Use of Biosimilar Infliximab: Evidence-Based Analysis Using Healthcare Claim Database
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.1787
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
J. Cho
D. An
S. Jang
E. Lee
Publisher
Elsevier BV
Related search
PF-06438179/GP1111: An Infliximab Biosimilar
BioDrugs
Medicine
Biotechnology
Pharmacology
Efficacious Transition From Reference Infliximab to Biosimilar Infliximab in Clinical Practice
International Journal of Rheumatic Diseases
Rheumatology
The Future of Biosimilar Insulins
Diabetes Spectrum
Internal Medicine
Endocrinology
Metabolism
Diabetes
Budget Impact Analysis of Biosimilar Infliximab for the Treatment of Crohn's Disease in Six Central Eastern European Countries
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Does a Mandatory Non-Medical Switch From Originator to Biosimilar Infliximab Lead to Increased Use of Outpatient Healthcare Resources? A Register-Based Study in Patients With Inflammatory Arthritis
RMD Open
Rheumatology
Allergy
Immunology
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
BioDrugs
Medicine
Biotechnology
Pharmacology
The Future Is Bright
Vital
The Future Looks Bright
Lighting Research and Technology
Electronic Engineering
Electrical
The Future Is Bright for Emissive Technologies
Information Display
Hardware
Electronic Engineering
Electrical
Architecture
